Returns rising for Forest shareholders as Actavis gains continue
This article was originally published in Scrip
Executive Summary
Actavis revealed double-digit sales gains on 20 February, which caused the generic drug maker and burgeoning specialty pharmaceutical player to reach a new stock price high for the third day in a row.